Aegis Trims PT on Synergy (SGYP) to $26 Following Q1 Results; Updates on N-T Catalysts
Tweet Send to a Friend
Aegis Capital cuts its price target on Synergy Pharmaceuticals (Nasdaq: SGYP) from $28 down to $26 while affirming its Buy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE